




Explore Cereblon Modulation in Multiple Myeloma

Based on In Vitro Studies¹⁻⁵

Tap to learn how cereblon-modulating agents exert their tumoricidal activity



Cereblon-modulating agents



Tap to learn how cereblon-modulating agents exert their immune stimulatory activity


IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

HOME

Role of Oncogenes in Myeloma Cell Activity

Based on In Vitro Studies



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


IMiD[®] and CELMoD[®] are registered trademarks of Bristol-Myers Squibb Company.
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21

[References](#)

HOME

Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies




IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

HOME

Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies




IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

HOME

T-Cell Activity in Multiple Myeloma

Based on In Vitro Studies




IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

HOME

Cereblon Modulation Inside a T Cell

Based on In Vitro Studies




IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

HOME

Cereblon Modulation Inside a T Cell

Based on In Vitro Studies



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD® and CELMoD® are registered trademarks of Bristol-Myers Squibb Company.
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21

[References](#)